<![CDATA[Polpharma Biologics S.A. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=48687>Thu, 30 Apr 2026 10:48:32 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases]]>https://www.newswire.co.kr/newsRead.php?no=1025167Thu, 11 Dec 2025 17:50:00 +0900<![CDATA[폴파마 바이오로직스-립스 파마세우티카, 자가면역질환 바이오시밀러 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1025168Thu, 11 Dec 2025 17:50:00 +0900<![CDATA[Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars]]>https://www.newswire.co.kr/newsRead.php?no=1017972Wed, 03 Sep 2025 16:40:00 +0900<![CDATA[폴파마 바이오로직스-MS 파마, 바이오시밀러 후보물질 베돌리주맙·오크렐리주맙·구셀쿠맙 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1017977Wed, 03 Sep 2025 16:40:00 +0900<![CDATA[Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016]]>https://www.newswire.co.kr/newsRead.php?no=1016426Fri, 08 Aug 2025 17:10:00 +0900<![CDATA[폴파마 바이오로직스, 프레제니우스 카비와 베돌리주맙 바이오시밀러 PB016 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1016427Fri, 08 Aug 2025 17:10:00 +0900